95 related articles for article (PubMed ID: 21930168)
1. Heparin-triggered release of camouflaged tissue plasminogen activator for targeted thrombolysis.
Absar S; Choi S; Yang VC; Kwon YM
J Control Release; 2012 Jan; 157(1):46-54. PubMed ID: 21930168
[TBL] [Abstract][Full Text] [Related]
2. Preparation and characterization of anionic oligopeptide-modified tissue plasminogen activator for triggered delivery: an approach for localized thrombolysis.
Absar S; Choi S; Ahsan F; Cobos E; Yang VC; Kwon YM
Thromb Res; 2013 Mar; 131(3):e91-9. PubMed ID: 23269380
[TBL] [Abstract][Full Text] [Related]
3. Bio-responsive delivery of tissue plasminogen activator for localized thrombolysis.
Absar S; Kwon YM; Ahsan F
J Control Release; 2014 Mar; 177():42-50. PubMed ID: 24417965
[TBL] [Abstract][Full Text] [Related]
4. Synthetic, organic compound vepoloxamer (P-188) potentiates tissue plasminogen activator.
Dansdill D; Halandras PM; Beverly J; Jeske W; Hoppensteadt D; Emanuele M; Fareed J; Cho JS
J Vasc Surg; 2018 Jan; 67(1):294-299. PubMed ID: 27939143
[TBL] [Abstract][Full Text] [Related]
5. ATTEMPTS: a heparin/protamine-based prodrug approach for delivery of thrombolytic drugs.
Liang JF; Park YJ; Song H; Li YT; Yang VC
J Control Release; 2001 May; 72(1-3):145-56. PubMed ID: 11389993
[TBL] [Abstract][Full Text] [Related]
6. Construction and characterization of a t-PA mutant for use in ATTEMPTS: a drug delivery system for achieving targeted thrombolysis.
Yang VC; Naik SS; Song H; Dombkowski AA; Crippen G; Liang JF
J Control Release; 2005 Dec; 110(1):164-76. PubMed ID: 16260060
[TBL] [Abstract][Full Text] [Related]
7. Application of "ATTEMPTS" for drug delivery.
Naik SS; Liang JF; Park YJ; Lee WK; Yang VC
J Control Release; 2005 Jan; 101(1-3):35-45. PubMed ID: 15588892
[TBL] [Abstract][Full Text] [Related]
8. ATTEMPTS: a heparin/protamine-based delivery system for enzyme drugs.
Liang JF; Li YT; Song H; Park YJ; Naik SS; Yang VC
J Control Release; 2002 Jan; 78(1-3):67-79. PubMed ID: 11772450
[TBL] [Abstract][Full Text] [Related]
9. Serum albumin-protamine conjugate for biocompatible platform for targeted delivery of therapeutic macromolecules.
Absar S; Nahar K; Choi S; Ahsan F; Yang VC; Kwon YM
J Biomed Mater Res A; 2014 Aug; 102(8):2481-90. PubMed ID: 23946132
[TBL] [Abstract][Full Text] [Related]
10. Systemic thrombolysis of portal vein thrombosis in cirrhotic patients: a pilot study.
De Santis A; Moscatelli R; Catalano C; Iannetti A; Gigliotti F; Cristofari F; Trapani S; Attili AF
Dig Liver Dis; 2010 Jun; 42(6):451-5. PubMed ID: 19819770
[TBL] [Abstract][Full Text] [Related]
11. A new drug delivery system for intravenous coronary thrombolysis with thrombus targeting and stealth activity recoverable by ultrasound.
Kawata H; Uesugi Y; Soeda T; Takemoto Y; Sung JH; Umaki K; Kato K; Ogiwara K; Nogami K; Ishigami K; Horii M; Uemura S; Shima M; Tabata Y; Saito Y
J Am Coll Cardiol; 2012 Dec; 60(24):2550-7. PubMed ID: 23158532
[TBL] [Abstract][Full Text] [Related]
12. Comparison of a low-molecular-weight heparin (nadroparin calcium) and unfractionated heparin as adjunct to coronary thrombolysis with alteplase and aspirin in dogs.
Jun L; Arnout J; Vanhove P; Dol F; Lormeau JC; Herbert JM; Collen D; Van de Werf F
Coron Artery Dis; 1995 Mar; 6(3):257-63. PubMed ID: 7788040
[TBL] [Abstract][Full Text] [Related]
13. Prophylactic fibrinolysis through selective dissolution of nascent clots by tPA-carrying erythrocytes.
Murciano JC; Medinilla S; Eslin D; Atochina E; Cines DB; Muzykantov VR
Nat Biotechnol; 2003 Aug; 21(8):891-6. PubMed ID: 12845330
[TBL] [Abstract][Full Text] [Related]
14. Effects of intrathrombic administration of prostaglandin E1 during pulse-spray thrombolysis with tissue-type plasminogen activator in experimental thrombosis.
Valji K; Bookstein JJ
Radiology; 1993 Mar; 186(3):873-6. PubMed ID: 8430201
[TBL] [Abstract][Full Text] [Related]
15. Augmented experimental pulse-spray thrombolysis with tissue plasminogen activator, enabling dose reduction by one or more orders of magnitude.
Bookstein JJ; Bookstein FL
J Vasc Interv Radiol; 2000 Mar; 11(3):299-303. PubMed ID: 10735423
[TBL] [Abstract][Full Text] [Related]
16. Cerebral venous congestion as indication for thrombolytic treatment.
Tsai FY; Kostanian V; Rivera M; Lee KW; Chen CC; Nguyen TH
Cardiovasc Intervent Radiol; 2007; 30(4):675-87. PubMed ID: 17573553
[TBL] [Abstract][Full Text] [Related]
17. A prodrug approach for delivery of t-PA: construction of the cationic t-PA prodrug by a recombinant method and preliminary in vitro evaluation of the construct.
Song H; Liang JF; Yang VC
ASAIO J; 2000; 46(6):663-8. PubMed ID: 11110262
[TBL] [Abstract][Full Text] [Related]
18. An activated-platelet-sensitive nanocarrier enables targeted delivery of tissue plasminogen activator for effective thrombolytic therapy.
Huang Y; Yu L; Ren J; Gu B; Longstaff C; Hughes AD; Thom SA; Xu XY; Chen R
J Control Release; 2019 Apr; 300():1-12. PubMed ID: 30807804
[TBL] [Abstract][Full Text] [Related]
19. A novel heparin/protamine-based pro-drug type delivery system for protease drugs.
Liang JF; Song H; Li YT; Yang VC
J Pharm Sci; 2000 May; 89(5):664-73. PubMed ID: 10756332
[TBL] [Abstract][Full Text] [Related]
20. Influence of selective endoperoxide/thromboxane A2 receptor antagonism with sulotroban on lysis time and reocclusion rate after tissue plasminogen activator-induced coronary thrombolysis in the dog.
Shebuski RJ; Smith JM; Storer BL; Granett JR; Bugelski PJ
J Pharmacol Exp Ther; 1988 Aug; 246(2):790-6. PubMed ID: 3136245
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]